6986.TWO HeXun Biosciences Co., Ltd.

Healthcare Biotechnology Taiwan OTC Exchange
40.10 TWD
Close of Nov 6, 2026
39.40 71.28
Market cap
TWD 2.05B
P/E
16.0x
P/B
2.06x
ROE
12.3%
Dividend yield
0.46%
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6986.TWO undervalued?

Graham number
Price40.10
Graham value33.14
Premium21.0%

6986.TWO trades 21.0% above its Graham number.

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

HeXun Biosciences Co., Ltd. fundamental analysis

No fundamental analysis for HeXun Biosciences Co., Ltd. yet.

HeXun Biosciences Co., Ltd. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About HeXun Biosciences Co., Ltd.

HeXun Biosciences Co., Ltd. engages in the research and development of stem cell drug development and cardiovascular disease treatments in Taiwan. It provides contract manufacturing; commissioned inspection; aseptic filling; and consulting services. The company was founded in 2019 and is based in Taoyuan City, Taiwan.

Full company profile